Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Octaviana F., Bestari A., Loho A., Indrawati L., Wiratman W., Kurniawan M., Sugiarto A., Budikayanti A.
26029958700;57223262097;57223264641;57205117182;57191920526;57196001182;57189612291;57194713932;
Nonconvulsive Status Epilepticus in Metabolic Encephalopathy in Indonesia Referral Hospital
2021
Neurology India
69
2
354
359
1
Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Octaviana, F., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Bestari, A., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Loho, A., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Indrawati, L., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Wiratman, W., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Kurniawan, M., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Sugiarto, A., Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Budikayanti, A., Department of Neurology, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Background: Nonconvulsive status epilepticus (NCSE) is often underdiagnosed in patients with metabolic encephalopathy (ME). The diagnosis of ME should be made specifically to recognize the underlying etiology. Delay in seizure identification and making a diagnosis of NCSE contributed to the poor outcome. Objective: This study aimed to find the incidence and outcome of NCSE in patients with ME. Methods and Material: This was an observational prospective cross-sectional study in patients with ME in emergency and critical care units in Cipto Mangunkusumo General Hospital. The diagnosis of NCSE was based on EEG using Salzburg Criteria for Nonconvulsive Status Epilepticus (SCNC). The outcome was assessed within 30 days after the NCSE diagnosis has been made. Results: A total of 50 patients with ME were involved in this study. NCSE was confirmed in 32 subjects (64%). The most common etiology of ME was sepsis (58%). The mortality rate in the NCSE and non-NCSE group was 40.6% vs 44.4%. Multiple aetiologies were risk factors to poor outcome in the NCSE group. Conclusions: The incidence of NCSE among patients with ME at our hospital was high. Despite the anti-epileptic treatment of the NCSE group, the underlying cause of ME is still the main factor that affected the outcome. Therefore, aggressive treatment of anti-epileptic drug (AED) should be very carefully considered knowing the possible side-effect that might worsen the outcome of patients with ME. ? 2021 Wolters Kluwer Medknow Publications. All rights reserved.
Metabolic encephalopathy; mortality; non-convulsive status epilepticus
diazepam; levetiracetam; midazolam; phenobarbital; phenytoin; propofol; valproic acid; adult; Article; clinical article; cross-sectional study; electroencephalography; epileptic state; female; human; incidence; Indonesia; male; metabolic encephalopathy; mortality rate; nonconvulsive status epilepticus; observational study; prognosis; risk factor; sepsis; epileptic state; hospital; metabolic encephalopathy; patient referral; prospective study; Brain Diseases, Metabolic; Cross-Sectional Studies; Electroencephalography; Hospitals; Humans; Indonesia; Prospective Studies; Referral and Consultation; Status Epilepticus
Wolters Kluwer Medknow Publications
283886
33904451
Article
Q3
339
13675